SBIR/STTR Research Award

DURING THE PAST SEVERAL YEARS, MEASUREMENT OF CREATINE KINASE-MB ISOENZYME (CK-MB) IN SERUM HAS BECOME A VERY POPULAR ASSAY TO DISTINGUISH BETWEEN PATIENTS WITH ACUTE MYOCARDIAL INFARCTIONS (AMI) AND THOSE WITH CHEST PAINS OF OTHER ETIOLOGY.

Award identifier 2b792756a6ec6cc69a9d287b4d96496c43c71d6346f0680818a32bde56533ddeAwarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1985

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Diagnostic Systems Laboratorie
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DURING THE PAST SEVERAL YEARS, MEASUREMENT OF CREATINE KINASE-MB ISOENZYME (CK-MB) IN SERUM HAS BECOME A VERY POPULAR ASSAY TO DISTINGUISH BETWEEN PATIENTS WITH ACUTE MYOCARDIAL INFARCTIONS (AMI) AND THOSE WITH CHEST PAINS OF OTHER ETIOLOGY. CK EXISTS PRIMARILY AS THREE ISOENZYMES: BB, WHICH IS PRESENT IN BRAIN; MB, WHICH PRIMARILY EXISTS IN HEART MUSCLE; AND MM, WHICH IS PRESENT BOTH IN HEART AND SKELETAL MUSCLES. CURRENT METHODS FOR MEASURING MB INCLUDE ELECTROPHORESIS, COLUMN CHROMATOGRAPHY, ENZYME INHIBITION, AND RADIOIMMUNOSSAY (RIA). ALTHOUGH THE ABOVE METHODS ARE USEFUL IN MEASURING MB IN SERUM, THERE ARE INHERENT LIMITATIONS IN THESE METHODS. ELECTROPHORESIS AND CHROMATOGRAPHY ARE NOT SENSITIVE, AND THUS PRECISE QUANTITATION OF MB AT THE LOWER LEVEL BECOMES DIFFICULT. ENZYME INHIBITION AND RIA METHODS, ALTHOUGH QUITE SENSITIVE, MAY NOT BE SPECIFIC ALL THE TIME BECAUSE THEY MEASURE B SUBUNIT OF BOTH MB AND BB AND ALSO CROSS-REACT WITH THE MACROMOLECULAR FORMS OF CK. THREE COMMERCIAL KITS ARE AVAILABLE WHICH MEASURE SPECIFIC MB ISOENZYME: TWO USE SOLID-PHASE SANDWICH IMMUNOASSAY TECHNIQUE AND THE OTHER USES A COMBINATION OF ENZYME INHIBITION AND PRECIPITATION METHODS. STABILITY OF THE COMPONENTS, CUMBERSOME METHODOLOGY, AND POOR SENSITIVITY POSE PROBLEMS IN THE FIRST METHOD; AND THE SECOND IS A VERY TIME-CONSUMING MANUAL METHOD WHOSE COMPLETE AUTOMATION IS DIFFICULT. FOR THESE REASONS DSL, IN COLLABORATION WITH THE UTHSC AT DALLAS, WILL DEVELOP AN ASSAY WHICH WILL SPECIFICALLY MEASURE CK-MB IN SERUM WITHOUT CROSS-REACTIVITY TO OTHER FORMS OF CK. THE PROPOSED METHOD IS TO PREPARE A MONOCLONAL ANTIBODY USING HYBRID CELL TECHNIQUES TO THE CHEMICALLY WELL-DEFINED PURE PROTEIN ANTIGEN, HUMAN HEART (H)CK-MB. SUCH MONOCLONAL ANTIBODY SHOULD BE MONOSPECIFIC IN TERMS OF BINDING TO A UNIQUE DETERMINANT ON THE IMMUNOGEN MOLECULE, CK-MB, AND NOT BE REACTIVE WITH OTHER FORMS OF CK. THIS ANTIBODY WILL THEN BE USED TO DEVELOP A SIMPLE IMMUNOASSAY TO MEASURE SPECIFICALLY CK-MB IN SERUM.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.